{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:37:32Z","timestamp":1761237452438},"reference-count":0,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Technology Analysis & Strategic Management"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1080\/09537320500088815","type":"journal-article","created":{"date-parts":[[2007,7,8]],"date-time":"2007-07-08T21:54:08Z","timestamp":1183931648000},"page":"183-204","source":"Crossref","is-referenced-by-count":4,"title":["From the \u2018rhetoric of hope\u2019 to the \u2018patient-active paradigm\u2019\u2014strategic positioning of pharmaceutical and biotechnology companies"],"prefix":"10.1080","volume":"17","author":[{"given":"D. Jane","family":"Bower","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","container-title":["Technology Analysis & Strategic Management"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/09537320500088815","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,12,18]],"date-time":"2016-12-18T08:24:17Z","timestamp":1482049457000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/09537320500088815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["10.1080\/09537320500088815"],"URL":"https:\/\/doi.org\/10.1080\/09537320500088815","relation":{},"ISSN":["0953-7325","1465-3990"],"issn-type":[{"value":"0953-7325","type":"print"},{"value":"1465-3990","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}